Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus NATESTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus NATESTO.
ANDROID 10 vs NATESTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Testosterone replacement therapy; testosterone binds to androgen receptors, activating gene transcription for male sexual development and maintenance of secondary sexual characteristics.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
One 10 mg buccal tablet applied twice daily to the gum region above the incisor tooth, approximately 12 hours apart; morning and evening.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
The terminal elimination half-life of testosterone after intramuscular injection of testosterone enanthate is approximately 8 days (range 4–12 days), reflecting slow absorption from the oily depot. This prolonged half-life supports a dosing interval of every 2–4 weeks.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Following intramuscular administration of testosterone enanthate, approximately 90% of the dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (e.g., androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone in urine is negligible (<1%).
Category C
Category C
Androgen
Androgen